Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate Intravesical Valrubicin (AD 32) After TURBT for Superficial Bladder Cancer
NCT00003725Phase 3Unknown
- Sponsor
- Anthra Pharmaceuticals, Inc.
- Start
- Dec 1996
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of valrubicin in bladder cancer (2 arms), sponsored by Anthra Pharmaceuticals, Inc. Primary endpoints: Efficacy of adjuvant AD 32 at 2 years and Toxicity of AD 32. Status: unknown.
02
Drugs
valrubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00003725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003725.